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Abstract In 2000, the Clinical Trials Subcommittee of
the International Headache Society (IHS) published the
second edition of its guidelines for controlled trials of
drugs in migraine. The purpose of this publication was to
improve the quality of such trials by increasing the
awareness amongst investigators of the methodological
issues specific to this particular illness. Until now the
adherence to these guidelines has not been systematically
assessed. We reviewed all published controlled trials of
drugs in migraine from 2002 to 2008. Eligible trials were
scored for compliance with the IHS guidelines by using
grading scales based on the most essential recommenda-
tions of the guidelines. The primary efficacy measure of
each trial was also recorded. A total of 145 trials of acute
treatment and 52 trials of prophylactic treatment were
eligible for review. Of the randomized, double-blind trials,
acute trials scored an average of 4.7 out of 7 while pro-
phylactic trials scored an average of 5.6 out of 9 for
compliance. Thirty-one percent of acute trials and 72% of
prophylactic trials used the recommended primary efficacy
measure. Fourteen percent of the reviewed trials were
either not randomized or not double-blinded. Adherence
to international guidelines like these of IHS is important to
ensure that only high-quality trials are performed, and to
provide the consensus that is required for meta analyses.
The primary efficacy measure for trials of acute treatment
should be ‘‘pain free’’ and not ‘‘headache relief’’. Open-
label or non-randomized trials generally have no place in
the study of migraine drugs.
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Introduction
The last major breakthrough in acute migraine treatment
was the introduction of the triptans in the beginning of the
1990s. The triptans have now become the gold standard for
acute migraine therapy [1] although their superiority over
analgesics has been questioned [2]. However, not all
patients respond to triptans [3] and triptans are used only
by a minority (10–15%) of migraine patients [4, 5]. The
triptans have, thus, probably not reduced migraine-related
abeseteeism and socio-economic costs [6].
No currently marketed drug has been developed spe-
cifically for the prevention of migraine. Several drugs have,
however, been shown to effectively reduce attack fre-
quency in some patients, but these drugs are often associ-
ated with adverse effects that can be intolerable [7]. Thus,
there is a large need for developing new therapies for the
treatment of migraine.
In recent years, several candidates for pharmacological
treatment of migraine has been discovered, such as
CGRP-antagonists [8], NOS-inhibitors [9] and tonabersat
[10, 11]. As a consequence, a large number of clinical
trials in migraine are currently being carried out and many
more will be carried out in the years to come. Possibly
these studies will show new substances to be more
effective and better tolerable in comparison with current
treatments.
In order for the multi-million dollar investments going
into these trials to truly benefit the migraineurs and in
the end reduce the global burden of migraine, it must be
ensured that the trials are internally and externally valid
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and that publication bias [12] does not take place. Also, to
allow for comparison of trial outcomes and an international
collaboration on drug development and therapy for migraine,
there must, at least to some extent, be a global agreement on
trial design and the parameters used for the assessment of
efficacy, adverse events and safety.
In order to address these specific methodological prob-
lems and to generally improve the quality of migraine trials
the Clinical Trials Subcommittee of the International
Headache Society (IHS) published the first edition of its
guidelines for controlled trials of drugs in migraine in 1991
[13].These guidelines consist of a series of recommenda-
tions, with comments, for the selection of patients, trial
design, evaluation of results and the use of statistics. The
second edition of these guidelines was published in 2000
[14], amongst other changes introducing additional rec-
ommendations for efficacy measures in acute trials.
In 2007, The European Medicines Agency published
Guidelines on Clinical Investigation of Medicinal Products
for the Treatment of migraine [15] and these guidelines are
mainly based on the IHS guidelines with the same primary
efficacy parameters.
Thus, these recommendations have been widely elabo-
rated and disseminated but it has not been systematically
assessed to what extent they are actually followed by
investigators.
The objective of this review was to assess to what extent
clinical drug trials in migraine carried out from 2002 until
2008 followed the 2000 IHS guidelines.
Methods
Criteria for considering studies for this review
Studies were required to be prospective controlled trials of
pharmacological interventions for the treatment of migraine
attacks, either acute treatment or preventive treatment.
Migraine could be with and/or without aura, special types of
migraine or unspecified.
Study participants were required to be adults (aged
18 years or older).
The publication dates for the studies were between 2002
and 2008, both years inclusive.
The following were excluded from the review:
• Studies of combined pharmacological and non-phar-
macological treatment.
• Studies reported only in languages other than English,
German, Swedish, Norwegian or Danish.
• Studies not concerning migraine exclusively (e.g.
migraine and tension-type headache or migraine and
depression).
• Studies of pharmacokinetics and/or pharmacodynamics
exclusively.
• Studies of safety and tolerability exclusively.
• Studies with non-clinical outcome measures only (e.g.
blood samples, MRI, EEG).
• Studies of induced migraine.
Search methods
PubMed was searched using the Cochrane Highly Sensitive
Search Strategy (HSSS) for PubMed (as revised 2008) [16]
and with publication date limits ranging from January 1,
2002 until December 31, 2008. The entire search string
thus being: ‘‘‘2002/01/01’[Publication Date]: ‘2008/12/
31’[Publication Date] AND (migraine AND (randomized
controlled trial OR randomized OR placebo OR drug
therapy OR randomly OR trial OR groups) NOT animals
NOT (humans and animals))’’.
The Cochrane Central Register of Controlled Trials
(CENTRAL) was searched using the word ‘‘migraine’’.
Clinicaltrials.gov was searched using the word
‘‘migraine’’ and with the following criteria: ‘‘Study type:
Interventional studies’’, ‘‘Age group: Adult (18–65) and
Senior (66?)’’.
Furthermore, trials were identified by searching refer-
ence lists of review articles.
Eligibility
Titles and abstracts of studies identified by the literature
search were screened for eligibility. Papers that could not
be excluded with certainty on the basis of information
contained in the title and/or abstract were retrieved in full
for screening.
Data extraction and analysis
Trials were divided into trials dealing with acute treatment
and trials dealing with prophylactic treatment.
Of the various points of recommendations listed in the
2000 IHS guidelines some are optional and some only
apply to special types of trials. Only a few can be regarded
as generally essential.
For the evaluation of the trials in this review simplified
version of the guidelines were developed containing only
the recommendations which were deemed essential and
presented in an unambiguous way which allows for clear
judgment of whether the trial follows the guidelines on
each point.
Based on this simplified version of the guidelines two
schedules for the evaluation of drug trials dealing with acute
and prophylactic treatment, respectively, were developed in
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which a trial is assigned one point for each guideline
requirement met and 0 for each of those that are not. The
evaluation schedules are shown in Table 1, 2.
In addition, the following were registered for each trial:
publication date, size (number of treated patients),
‘‘setting’’ (neurology, emergency medicine, internal medi-
cine, general practice or other), location (US, Europe,
other, multinational) and the diagnosis of patients treated in
the trial.
For trials not using the recommended primary outcome
measure the outcome measure actually used was registered.
For the prophylactic trials the following were also reg-
istered: whether the trial design was cross-over or parallel-
group, the duration of the treatment period and the attack
frequency required for inclusion.
Acute trials could score a maximum of seven points,
prophylactic trials a maximum of nine points, items.
To evaluate compliance with the IHS guidelines the
following measures were defined a priori: mean score of
randomized, double-blind (RDB) trials, mean score of all
reviewed trials, percentage of trials either not randomized
or not double-blind (non-RDB), percentage of RDB trials
using the recommended primary efficacy measure, per-
centage of RDB trials that are placebo-controlled.
Results
Data collection
The search was performed on August 12, 2009. Searching
Pubmed using HSSS retrieved 3,296 items. Searching
CENTRAL retrieved 2,169 items and searching clinical-
trials.gov retrieved 233 items.
Of the 5,698 titles and abstracts screened 255 papers
were retrieved in full. 12 papers were unretrievable. A total
of 184 retrievable papers, containing reports on 145 acute
[17–148] and 52 prophylactic trials [149–198], were con-
sidered eligible for further review.
Evaluation of trials
The IHS diagnostic criteria were used in by far the most
studies (92% of acute trials and 98% of prophylactic trials).
The reports of studies that did not use IHS criteria did not
mention the diagnostic criteria actually used, simply stated
that a physician had diagnosed the patients or used modi-
fied IHS criteria (e.g. ‘‘at least three items from the list of
criteria’’[113]).
The median number of treated subjects in the acute trials
was 328 (range 12–5,388) while the median number of
treated subjects in the prophylactic trials was 88 (range
14–818). 47% of acute trials and 37% of prophylactic trials
were carried out in the US. 89% of both acute trials and
prophylactic trials were carried out within a neurological
setting.
Thirty-one percent of acute RDB trials applied the
recommended ‘‘pain free at 2 h’’ as the primary efficacy
Table 1 Schedules for evaluation of clinical trials in migraine
Acute
Selection of patients
Do the diagnostic criteria conform to those of the IHS? (?1/?0)
Trial design
Is the trial double blind? (?1/?0)
Is the trial placebo-controlled? (?1/?0)




Is the percentage of patients pain-free at 2 h used as a primary
measure of efficacy? (?1/?0)
Is sustained pain-free (percentage of patients pain-free within
2 h with no use of rescue medication or relapse within 48 h)
used as a measure of efficacy? (?1/?0)
Is ‘‘headache relief’’ (percentage of patients with a decrease in
headache from severe or moderate to none or mild within 2 h
before any rescue medication) used as a measure of efficacy?
(?1/?0)
Other
Is the percentage of patients pain-free at 2 h used as a
secondary measure of efficacy?
Is sustained pain-free (percentage of patients pain-free within
2 h with no use of rescue medication or relapse within 24 h)
used as a measure of efficacy?
Prophylaxis
Selection of patients
Do the diagnostic criteria conform to those of the IHS? (?1/?0)
Do the patients’ attacks of migraine occur 2–6 times per month?
(?1/?0)
Trial design
Is the trial double blind? (?1/?0)
Is the trial placebo-controlled? (?1/?0)
Were the trial participants randomized at entry to the trial?
(?1/?0)
Were the trial participants stratified for frequency of migraine
attacks occurring during baseline? (?1/?0)
Are treatment periods of at least 3 months used? (?1/?0)
Evaluation of results
IHS recommended
Is frequency of migraine attacks per 4 weeks used as a primary
measure of efficacy? (?1/?0)
Is the number of days with migraine per 4 weeks used as a
measure of efficacy? (?1/?0)
Other
Is the number of days with headache per 4 weeks used as a
measure of efficacy?
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measure while 49% of acute RDB trials applied this mea-
sure as a secondary endpoint. ‘‘Headache relief’’ (a decrease
from moderate or severe headache to none or mild) was the
primary efficacy measure in 39% of the reviewed acute
RDB trials. The ‘‘sustained pain free’’ endpoint was only
used by 5 (3%) acute trials. However, 68 (47%) of acute
trials used a modified and less rigorous version of this
efficacy measure: the percentage of patients that sustained
pain-free state at 24 h instead of the recommended 48 h.
More than 86% of prophylactic trials used the recom-
mended treatment duration of at least 3 months. The
average treatment duration was 16.0 weeks. Only 3 (6%) of
the reviewed prophylactic trials applied stratification for
migraine attack frequency. Seven of the prophylactic
studies (14%) used the recommended migraine attack fre-
quency of 2–6 as an eligibility criterion. Most studies
required an average attack frequency of different intervals
between 3 and 12 attacks per month. Eight study reports
did not mention an attack frequency requirement. 72% of
the prophylactic studies used the recommended ‘‘migraine
attacks per 4 weeks’’ as the primary efficacy measure.
Discussion
The IHS guidelines for drug trials in migraine consist of a
series of recommendations with comments. Some recom-
mendations in the guidelines are general for randomised
clinical trials (RCTs), such as randomisation, double-
blinding and placebo-control. These recommendations are
followed in 67% of the clinical studies. Other recommen-
dations are migraine-specific, such as operational diag-
nostic criteria and primary efficacy measure. Amongst
these recommendations the use of operational diagnostic
criteria is a major contributor to the external validity of the
results of the RCT. The IHS diagnostic criteria were used
in 94% of the RCTs Fig. 1, 2.
The choice of a primary efficacy measure is crucial
when designing a drug trial. It is also important that the
same primary efficacy is used in similar RCTs when meta-
analyses are performed. Some consensus internationally is
therefore needed and international guidelines like these
of IHS are suggested in order to provide this consensus.
In the first IHS guidelines ‘complete response’ [13], which
was very similar to current ‘‘sustained pain-free’’ [14] was
suggested as the primary efficacy measure. At the same
time Glaxo used, in the extensive trial programme of
sumatriptan, its so-called ‘‘Glaxo criterion’’: a decrease in
headache from severe or moderate to none or mild [199].
This ‘headache relief’ was subsequently used in the
extensive trial programs of the triptans, naratriptan,
zolmitriptan, rizatriptan, almotriptan, eletriptan and frova-
triptan in the 1990s [1] and its use persisted into the 2010s
[200]. In 2000, pain-free after 2 h was recommended as the
primary efficacy parameter by IHS. Only 31% of the RCTs
of acute treatment reviewed here comply with this rec-
ommendation. However, this endpoint has been used in an
increasing number of RCTs (Fig. 3).
Table 2 Results
Acute Prophylaxis
Mean score of RDB trials 4.7 (range 2–6) 5.6 (range 4–9)
Mean score of all reviewed trials 4.4 (range 0–6) 5.1 (range 1–9)
Percentage of non-RDB trials 15.2% (22 of 145) 9.6% (5 of 52)
Percentage of RDB trials using the
recommended primary efficacy measure
30.9% (38 of 123) 72.3% (34 of 47)
Percentage of RDB trials placebo-controlled 82.9% (102 of 123) 76.6% (36 of 47)
Fig. 1 Average scores for acute trials
Fig. 2 Average scores for prophylactic trials
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Studies of patient satisfaction have consistently shown
that patients consider complete relief of pain, a fast onset of
action and no pain recurrence the most desirable effects of
a migraine drug for acute treatment [201, 202]. While the
‘‘headache relief’’ endpoint is an effective measurement of
patients’ response to treatment it, thus, does not reflect
what patients actually consider important. Furthermore,
‘‘headache relief’’ has a much higher placebo rate than
‘‘pain free’’ [203].
Some of the acute trials apply even more rigorous pri-
mary efficacy endpoints, such as ‘‘pain free at 30 min’’ [82]
or ‘‘total symptom relief at 1 h’’ [59]. Nearly 50% of the
acute trials use the composite endpoint of ‘‘sustained pain
free’’ either for 24 or 48 h. ‘‘Sustained pain free’’ is
probably the ideal drug response in regard to patients’
requests. It is obtained, however, in only 20–30% of triptan
trials [3].
A few of the acute trials do not have the treatment of
headache as their primary objective. These trials focus on
the accompanying symptoms of nausea, photophobia and
phonophobia. This is acceptable and clinically relevant
since some migraineurs consider these symptoms to be the
main problem.
Several of the acute trials investigate the relationship
between the timing of drug intake (in relation to the onset
of migraine pain or cutaneous allodynia) and drug efficacy
[23, 62, 73, 86, 102, 103, 122, 130]. The results of these
trials suggest that ‘‘early’’ triptan administration, while the
headache is mild, is more efficient in terms of pain-free
outcomes and reduced risk of recurrence when compared to
‘‘late’’ administration, when the headache is moderate to
severe.
In acute trials of migraine with aura exclusively, drugs
could be taken either during the aura phase or during the
headache phase [11]. An efficacy endpoint in such a trial
could very well be the duration of the aura, since many
patients suffering from migraine with aura are severely
disabled by the aura itself. Alternatively, the efficacy
measure could be whether the migraine headache occurs.
Some of these patients often or even exclusively have a
mild tension-type like headache following their aura [7].
These patients obviously regard their aura symptoms and
not their headache as the main problem.
The prophylactic trials comply well with using the rec-
ommended primary efficacy measure. There are currently
no studies of what effects patients specifically request from
preventive treatment. Possibilities could be lowering of
attack frequency, shortening of attack duration, ameliora-
tion of migraine intensity or less days of absence from work.
A recent study showed that patients generally prefer treat-
ments highly efficient in reducing attack frequency over
treatments causing few side-effects and requiring infrequent
dosing [204].
Stratification for frequency of migraine attacks is only
used by three of the reviewed prophylactic studies and
none of these make use of the baseline stratification in the
following statistical analyses. This is probably because
attack frequency per se is not thought of as an important
prognostic factor for treatment response. This is unfortu-
nate as this has previously been shown to be the case [205]
and the knowledge that could be obtained by stratification
could be clinically useful and serve as a basis for further
studies.
The recommended attack frequency requirement of 2–6
attacks per month for preventive trials has not gained
popularity. It should be noted that this requirement is not
feasible for some studies of the migraine subtypes which is
obvious for chronic migraine and for menstrually related
migraine (MRM).
Specific guidelines for trials in chronic migraine have
recently been published in 2009 by the IHS [206] in which
the recommended primary endpoint depends on the study
objective but includes the number of headache days, the
number of migraine days or the number of migraine epi-
sodes. The four trials reviewed here adhere to this rec-
ommendation. Recommendations for trials in MRM
specifically are contained in the second edition of the IHS
guidelines.
Nearly 14% of the reviewed trials are either not ran-
domized or not double-blind. These studies are especially
prevalent amongst the acute trials. Open-label studies in
general are often smaller, explorative early phase studies.
For the non-RDB acute trials reviewed here, however, the
average number of treated patients is 556, i.e. larger than
the overall average of the acute trials. Three huge studies of
Fig. 3 Number of trials using ‘‘2 h pain free’’ and ‘‘2 h pain relief’’,
respectively, as a primary efficacy endpoint
J Headache Pain (2010) 11:457–468 461
123
more than 2,300 subjects each contribute to this average
[18, 53, 72]. One of these trials scored a total of 0 on the
rating scale used in this review. Randomization and the
double-blind technique are generally considered to be the
cornerstones of quality trials. Because of the above-men-
tioned subjective nature and large placebo effect, this
especially holds true for migraine studies. In addition these
features are fairly cheap and easy to apply. In some special
cases it is not possible to effectively blind the investigator
(e.g. surgical procedures) or the patients (e.g. trials of drugs
with characteristic and commonly known side-effects). If
this is not the case, performing open-label or non-ran-
domized trials in migraine can hardly be considered any-
thing but unethical to both the patients treated and to the
rest of the scientific society.
Investigators should be careful when reporting the details
of their studies and avoid using ambiguous or implicit terms
or methods. For example, in this study it was found that
several studies did not specify that the diagnosis of migraine
was made based on the IHS criteria even though this was
highly possible as the investigators had used these criteria in
all of their previous studies. In some trials the word
‘‘headache’’ is used synonymously with migraine headache
even though ‘‘headache’’ of course could refer to all other
kinds of head pain. Thus, there is an important difference
between having ‘‘reduction of migraine days’’ or ‘‘reduction
of headache days’’ as an efficacy endpoint, especially
since migraineurs often experience tension-type headache
between migraine attacks (‘‘interval headache’’) [207].
Many prophylactic trials do not specify the attack frequency
required for eligibility even though this is highly relevant.
Most prophylactic trials also neglect the important aspect of
defining how long a time span between attacks is required
for the attacks to be regarded as separate and not a case of
recurrence.
This study is limited by its use of a very simplified
version of the IHS guidelines for assessing adherence.
Other elements of the guidelines could have been assessed
as well. Result accuracy could have been increased by
employing multiple reviewers. The reports reviewed were
published between 2002 and 2008. Some study protocols
have necessarily been written before the publication of the
2000 IHS guidelines. One study published in 2006 [145]
was actually done in 1988, i.e. before the publication of the
first edition of the IHS guidelines.
In conclusion, even though the quality of clinical trials
in migraine is generally high and the IHS recommendations
are well adhered to, there is still room for improvement.
Investigators should be encouraged to report meticulously
and to use clinically relevant primary efficacy measures.
The once popular ‘‘headache response’’ endpoint for acute
trials should now be considered obsolete. Stratification
should be applied in future parallel-group prophylactic
trials.
Open-label or non-randomized trials generally have no
place in the study of migraine drugs.
The IHS should develop specific guidelines for assess-
ment of effects of the timing of drug administration in
acute trials, e.g. by providing definitions of the terms
‘‘early migraine’’ and ‘‘mild migraine’’ as well as other
relevant phenomena such as cutaneous allodynia.
Furthermore, the IHS should offer specific guidelines for
migraine subtypes such as migraine with aura [208] and for
special treatments such as botulinum toxin injections and
similar complex regimens that could be seen in future
migraine trials.
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